quantisnow
FeedTopReportsPricing
⌘K
Live feed
19:10:00·1760d
PRRelease
Iovance Biotherapeutics Inc. logo
BridgeBio Pharma Inc. logo
Eidos Therapeutics, Inc. logo
+1

BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

IOVA· Iovance Biotherapeutics Inc.BBIO· BridgeBio Pharma Inc.EIDX· Eidos Therapeutics, Inc.BMEA· Biomea Fusion Inc.
Health Care
Original source

Companies

  • IOVA
    Iovance Biotherapeutics Inc.
    Health Care
  • BBIO
    BridgeBio Pharma Inc.
    Health Care
  • EIDX
    Eidos Therapeutics, Inc.
    Health Care
  • BMEA
    Biomea Fusion Inc.
    Health Care

Recent analyst ratings

  • Apr 9BBIOUpdateRBC Capital Mkts$100.00
  • Mar 10BBIOUpdateWilliam Blair-
  • Feb 25IOVAUpdateCitizens$5.00
  • Jan 28BBIOUpdateBarclays$157.00
  • Jan 13BMEAUpdateRodman & Renshaw$8.00
  • Jan 6BBIOUpdateMorgan Stanley$96.00

Related

  • PR1d
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
  • PR6d
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  • SEC6d
    SEC Form PRE 14A filed by Iovance Biotherapeutics Inc.
  • SEC7d
    Amendment: SEC Form SCHEDULE 13G/A filed by BridgeBio Pharma Inc.
  • INSIDER10d
    SEC Form 4 filed by Kumar Neil
  • SEC14d
    SEC Form 144 filed by BridgeBio Pharma Inc.
  • ANALYST14d
    RBC Capital Mkts initiated coverage on BridgeBio Pharma with a new price target
  • INSIDER20d
    SEC Form 4 filed by Erdtmann Rainer M
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022